Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinfutai
- Development stage
- Phase 3
- Lead developer
- Shenzhen Salubris Pharmaceuticals
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Xinfutai (recombinant teriparatide for injection) is a human parathyroid hormone (PTH) analog developed by Shenzhen Salubris Pharmaceuticals for the treatment of osteoporosis, particularly in postmenopausal women at high risk of fracture. It is composed of the identical 34 N-terminal amino acid sequence of the naturally occurring human parathyroid hormone. As an anabolic agent, Xinfutai binds to the parathyroid hormone receptor 1 (PTHR1) to stimulate osteoblast activity, promoting new bone synthesis, increasing bone mineral density, and improving bone structural integrity. It was the first biological product launched by Salubris Pharmaceuticals, expanding their portfolio into the orthopedics field.
- Brand names
- Xinfutai
- Other names
- Recombinant Teriparatide for Injectionteriparatide
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on Xinfutai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinfutai.